Tempus AI Wins FDA Clearance for Pulmonary Hypertension Diagnostic Tool, Expanding Its Clinical AI Footprint

Tempus AI, the Chicago-based precision medicine company best known for its genomic data platform and oncology testing portfolio, has secured FDA clearance for a new diagnostic tool targeting pulmonary hypertension. The clearance represents a meaningful expansion of Tempus's regulatory footprint beyond oncology, signaling the company's broader ambitions in using AI-driven clinical decision support across multiple disease areas.

The Technology

The newly cleared tool applies Tempus's signature approach of layering artificial intelligence over multimodal clinical data to surface actionable diagnostic insights for clinicians. Pulmonary hypertension is a notoriously difficult condition to diagnose in its early stages, often requiring a combination of imaging, hemodynamic measurement, and clinical history before a confident diagnosis can be reached. By integrating data streams that clinicians already generate in routine care, the Tempus tool aims to flag patients who may warrant further workup earlier in their disease course. While specific algorithmic details have not been disclosed, the clearance indicates the tool met FDA standards for analytical and clinical validity — a bar that continues to shape how AI-driven diagnostics enter the market.

Clinical Context

Pulmonary hypertension affects an estimated tens of millions of patients globally and carries a significant mortality burden, particularly when diagnosis is delayed. The condition sits at the intersection of cardiology and genomics in ways that make it a logical adjacency for Tempus. Heritable forms of pulmonary arterial hypertension, driven by variants in genes such as BMPR2, account for a meaningful proportion of cases, and genomic risk stratification is increasingly discussed in specialist guidelines. A diagnostic AI tool that helps referring physicians identify at-risk patients sooner could reduce the diagnostic odyssey that many patients currently endure, while also creating natural referral pathways into genomic and molecular workup pipelines. For health systems already using Tempus's oncology infrastructure, the new tool offers an incremental deployment rather than a wholesale technology adoption.

Market Impact

The clearance comes at a moment when Tempus is navigating the expectations that accompany its status as a publicly traded AI health company. Demonstrating regulatory traction across therapeutic areas beyond cancer strengthens the company's narrative that its platform is disease-agnostic and scalable. It also positions Tempus in a growing competitive field where companies including Guardant Health and Foundation Medicine have built durable businesses by pairing genomic science with rigorous regulatory strategy. FDA clearance, rather than mere laboratory validation, increasingly serves as the credibility threshold that health system procurement committees require before deploying AI diagnostic tools at scale.

For the genetic testing industry broadly, Tempus's expansion into cardiovascular disease diagnostics underscores that the next growth frontier lies in embedding genomic and AI-powered tools into the full continuum of chronic disease management, not just oncology.